Brilinta Contraindications

History of Intracranial Hemorrhage: BRILINTA is contraindicated in patients with a history of intracranial hemorrrhage (ICH) because of a high risk of recurrent ICH in this population (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Active Bleeding: BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage (see Warnings, Precautions and Adverse Reactions).
Severe Hepatic Impairment: BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins (see Pharmacology under Actions).
Hypersensitivity: BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product (see Adverse Reactions).
Co-administration with strong CYP3A4 inhibitors: Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as co-administration may lead to a substantial increase in exposure to ticagrelor.